Copyright
©The Author(s) 2019.
World J Meta-Anal. Jun 30, 2019; 7(6): 269-289
Published online Jun 30, 2019. doi: 10.13105/wjma.v7.i6.269
Published online Jun 30, 2019. doi: 10.13105/wjma.v7.i6.269
Table 5 Patient- and treatment- associated parameters after multivisceral resection for gastric cancer
Study | Resection margin (R0 vs R1) | Most common resected organs | Lymph node involvement | Age | Blood transfusion | Complications (AI) (Re-OP) | Other prognostic factors |
Carboni et al[39], 2005 | R0 61.5%; R1 27.7%; R2 10.8% | Spleen: 48%; Pancreas: 43%; Colon: 25% | 86.2% | 61 | NR | (1.5%) (1.5%) | Lymph-node involvement and metastatic disease |
Colen et al[37], 2004 | NR | Spleen: 62%; Pancreas 57%; Colon: 24% | NR | 67.5 | NR | 0% (NR) | NR |
D'Amato et al[38], 2004 | R0: 69% | Pancreas: 62%; Colon: 12% | NR | NR | NR | (0%) (NR) | NR |
Jeong et al[43], 2009 | R0: 78.3%; R+: 21.7% | Spleen: 47%; Pancreas: 61%; Colon: 24% | N+: 90.1% | 59 | NR | (6.7%) (11%) | Lymph-node and lymphovascular involvement |
Kim et al[35], 2009 | R0: 43%; R1: 15%; R2: 74% | Spleen: 38%; Pancreas: 29%; Colon: 56% | NR | NR | NR | (2.9%) (0%) | histologic type, M stage, peritoneal metastasis, curability and treatment groups |
Martin et al[36], 2002 | R0: 100% | Spleen: 67%; Pancreas: 19%; Colon: 6%; Liver: 4% Gallbladder: 7% | N0: 35% N+: 65% | 66 | NR | (NR) (NR) | Lymph-node involvement and > pT3 |
Oñate-Ocaña et al[32], 2008 | R0: 58.1%; R1: 18.9%; R2: 23% | Spleen: 68%; Pancreas: 26%; Colon: 12%; Liver: 9% | NR | NR | NR | (NR) (NR) | NR |
Ozer et al[44], 2009 | NR | Pancreas: 54%; Colon: 32%; Liver: 18% | NR | 58 | NR | (8.9%) (NR) | Advanced age, lymph node involvement, and resection of more than 1 additional organ were significant prognostic factors for survival. |
Persiani et al[46], 2008 | R0: 320; R1: 39; R2: 29% | Spleen: 84%; Pancreas: 25%; Colon: 10% | NR | 63.4 | NR | (NR) (NR) | Splenectomy, D2 lymphadenectomy, and age greater than 64 yr were the only factors predictive of overall morbidity |
Shchepotin et al[33], 1998 | NR | Spleen: 43%; Pancreas: 69%; Colon: 45% Liver: 29% | N+: 38.8% | NR | NR | (3.7%) (NR) | NR |
Isozaki et al[45], 2000 | NR | Pancreas + Spleen: 36%; Pancreatoduodenectomy: 7% | N0 = 13%; N1 = 36%; N2 = 25%; N3 = 12% | NR | NR | (NR) (NR) | Location of the tumor, lymph node metastasis, histological depth of invasion, and extent of lymph node dissection |
Molina et al[40], 2019 | R0: 94% | Pancreas (49%); Spleen (34%) Liver (29%). | N+: 80% | 64,5 | NR | (NR) (NR) | Lymph-node involvement and R1-status |
Mita et al[42], 2017 | R0: 82.5%; R1: 17.5% | Spleen 29.1%; Pancreas: 46.6%; Colon: 13.6%; Liver: 11.7% | N+: 84.5% | 70 | NR | (NR) (NR) | Resection status |
Vladov et al[38], 2015 | R0: 75% | Spleen: 76.7%; Pancreas:40%; Colon: 18.3%; Liver 15% | NR | NR | NR | (NR) (NR) | NR |
Tran et al[31], 2015 | R1: 15.5 | Spleen: 48%; Pancreas:27% Liver 14% Colon: 13% | N0: 34.5% | 64 | NR | (11.5%) (13.8%) | MVR with pancreatectomy, was significantly associated with decreased survival, along with T-stage, N stage, perineural invasion, and |
Pacelli et al[34], 2013 | R0: 38.4% | Pancreas 46; Colon 43 | N+: 89.3% | NR | NR | (7%) (NR) | Lymph-node involvement and incomplete resection |
- Citation: Nadiradze G, Yurttas C, Königsrainer A, Horvath P. Significance of multivisceral resections in oncologic surgery: A systematic review of the literature. World J Meta-Anal 2019; 7(6): 269-289
- URL: https://www.wjgnet.com/2308-3840/full/v7/i6/269.htm
- DOI: https://dx.doi.org/10.13105/wjma.v7.i6.269